Acuta Capital Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Acuta Capital Partners’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-255,000	Closed	-$11.2M	–	40
2019 Q2	$11.2M	Buy	255,000 +49,000	+24%	+$2.76M	3.97%	10
2019 Q1	$10.6M	Buy	206,000 +18,500	+10%	+$799K	5.04%	6
2018 Q4	$6.93M	Buy	187,500 +55,000	+42%	+$1.98M	5.29%	6
2018 Q3	$4.97M	Sell	132,500 -27,500	-17%	-$1.01M	1.77%	18
2018 Q2	$6.32M	Buy	+160,000	New	+$5.08M	1.13%	22

Other funds holding BHVN

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Acuta Capital Partners's BHVN Position: Q3 2019 in Review

Acuta Capital Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2019, closing a stake of 255,000 shares — an estimated $11.2M sold.

Acuta Capital Partners first reported a position in BHVN in Q2 2018 and held it in 5 quarters. The position peaked at $11.2M in Q2 2019. 184 funds tracked by Wall St. Rank hold BHVN as of Q3 2019.

Acuta Capital Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2019 after selling out during the quarter.
Acuta Capital Partners sold 255,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2019, an estimated $11.2M.
Acuta Capital Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2018 and held it in 5 quarters.
Acuta Capital Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $11.2M in Q2 2019.
184 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2019.

Based on Acuta Capital Partners's 13F filing for Q3 2019, filed 14 Nov 2019.